Investigating how interferon lambda helps fight skin infections
Antiviral and immunomodulatory effects of interferon lambda in the skin
['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11045076
This study is looking at how a special protein called interferon lambda helps protect the skin from herpes virus infections while keeping inflammation in check, using mice to learn more about how it works and how it can prevent serious skin problems.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11045076 on ClinicalTrials.gov |
What this research studies
This research explores the role of type III interferons, specifically interferon lambda (IFN-λ), in providing antiviral immunity at the skin's surface. By using a mouse model of herpes simplex virus type 1 (HSV-1) infection, the study examines how IFN-λ can control infections without causing excessive inflammation. The researchers aim to understand how IFN-λ signaling in skin cells and immune cells can prevent severe skin disease associated with HSV-1, particularly focusing on its effects on neutrophil activity during infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of herpes simplex virus infections or those at risk of developing severe skin lesions from such infections.
Not a fit: Patients who do not have a history of herpes simplex virus infections or related skin conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the body's ability to control skin infections with fewer side effects.
How similar studies have performed: Previous research has shown promising results with type III interferons in other contexts, suggesting potential for success in this novel application.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAZEAR, HELEN — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: LAZEAR, HELEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: acute infection